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Abstract
The prognosis of neurodegenerative disorders is clinically challenging due to the inexis-
tence of established biomarkers for predicting disease progression. Here, we performed an
exploratory cross-sectional, case-control study aimed at determining whether gene expres-
sion differences in peripheral blood may be used as a signature of Parkinson’s disease
(PD) progression, thereby shedding light into potential molecular mechanisms underlying
disease development. We compared transcriptional profiles in the blood from 34 PD
patients who developed postural instability within ten years with those of 33 patients who
did not develop postural instability within this time frame. Our study identified >200 differen-
tially expressed genes between the two groups. The expression of several of the genes
identified was previously found deregulated in animal models of PD and in PD patients. Rel-
evant genes were selected for validation by real-time PCR in a subset of patients. The
genes validated were linked to nucleic acid metabolism, mitochondria, immune response
and intracellular-transport. Interestingly, we also found deregulation of these genes in a
dopaminergic cell model of PD, a simple paradigm that can now be used to further dissect
the role of these molecular players on dopaminergic cell loss. Altogether, our study provides
preliminary evidence that expression changes in specific groups of genes and pathways,
detected in peripheral blood samples, may be correlated with differential PD progression.
Our exploratory study suggests that peripheral gene expression profiling may prove
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valuable for assisting in prediction of PD prognosis, and identifies novel culprits possibly
involved in dopaminergic cell death. Given the exploratory nature of our study, further inves-
tigations using independent, well-characterized cohorts will be essential in order to validate
our candidates as predictors of PD prognosis and to definitively confirm the value of gene
expression analysis in aiding patient stratification and therapeutic intervention.
Introduction
Parkinson’s Disease (PD) is a multi-system, disabling, insidiously progressive neurodegenera-
tive condition affecting 1–2% of the population over the age of 60 [1]. Currently, PD is incur-
able, and diagnosis relies on the clinical examination of the patient, as established diagnosis
criteria are based on the identification of parkinsonism, namely bradykinesia in combination
with either rest tremor, rigidity, or both [2, 3]. Also, once PD is diagnosed, there are no avail-
able non-clinical biomarkers to accurately predict the rate of disease progression and to achieve
a prognosis. Clinical progression is heterogenous [4]. Major milestones of disease severity, as
postural instability and dementia, when present, are considered to be sensible clinical predic-
tors of disease progression [5], but there are no universally accepted clinical markers to differ-
entiate slower or faster progression profiles before and after these milestones are achieved.
Thus, identifying molecular signatures that allow discriminating between different progression
rates might significantly assist the therapeutic strategy, and enable improved outcomes in clini-
cal trials [6–8]. Expression studies performed in easily accessible tissue, such as blood, showed
that peripheral cells recapitulate transcriptional changes occurring in neurodegenerative brain
[9, 10], and are valuable to identify novel mechanisms underlying PD [11, 12]. However, these
studies were designed to pinpoint relevant genes and pathways for the diagnosis of PD, and did
not search for markers to distinguish between different disease progression rates. Our study
aimed at investigating, for the first time, whether gene expression profiling of peripheral blood
samples would enable differentiating patients with rapid or slow PD progression. By analysing
our findings, together with those reported in previously published studies, we found that
altered expression of genes involved in nucleic acids metabolic process, immune response,
mitochondria, and intracellular-transport may form a strong signature discriminating slow
from rapid PD progression. Furthermore, we confirmed identical expression changes in a neu-
ronal, dopaminergic cell model of PD, suggesting that these peripheral transcriptional alter-
ations may report on relevant molecular pathways involved in degeneration of dopaminergic
neurons. Altogether, the findings from our exploratory study open novel perspectives for dis-
ease prognosis and for the development of new strategies for individualized intervention in
PD, setting now the stage for future studies in other neurodegenerative conditions aimed at
identifying molecular signatures of disease progression.
Materials and Methods
A schematic representation of the overall experimental design of this study is presented in S1 Fig.
Cohort assembly and clinical characterization of patients
Patients were consecutively recruited from the movement disorders outpatient clinic of the Lis-
bon University Hospital. The Research Ethics Board of the Lisbon Faculty of Medicine
approved the study. All participants gave written informed consent. Neurologists with exper-
tise in movement disorders interviewed and examined all cases. Inclusion criteria were a
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diagnosis of PD according to the UK Brain Bank criteria for idiopathic PD [13] and the pres-
ence of motor symptoms for 10 years or longer. This was selected as a cut-off point to perform
a cross-sectional evaluation and separate patients into two distinct groups with “Slow” or
“Fast” progression, depending on the absence or presence of postural instability, respectively.
Postural instability was chosen to discriminate groups because, as an axial symptom, it evolves
more rapidly than other motor features and is associated with poorer quality of life [5]. It is
present in around three quarters of patients at 10 years of disease duration [14, 15] and,
although heterogeneous in time to axial symptoms, patients with postural instability at 10
years represent a group that arrived faster to a level of higher disease burden as opposed to a
group without postural instability at this time. Postural instability was defined by item 3.12 of
the MDS-UPDRS, part III. Slow progression if scored 0 (no postural instability) and rapid pro-
gression if scored 1. The selection of this operational criterion was based on the consensual
recognition that the onset of balance problems is associated with the risk of falls, which corre-
sponds to a clear disability milestone in PD progression [16]. In addition, it is consensually
accepted that the absence of postural instability after 10 or more years of symptom onset corre-
sponds to a more benign disability profile that is associated with a slower progression of clinical
factors related with loss of autonomy [15]. Our study design focused on the evaluation of gene
expression differences in slow versus rapid progression patients and, therefore, we did not
include clinically healthy subjects. A structured interview was used to obtain detailed informa-
tion on PD history, family history of PD, antiparkinsonian treatment, comorbidities and con-
comitant medication. PD was assessed using the Movement Disorders Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS)[17] and the modified Hoehn and Yahr scales
(mHY), the Mini-Mental State Examination and the Schwab and England activities of daily liv-
ing scale (SE). If motor fluctuations were present, patients were assessed during Best-on period.
Included patients (n = 70) were operationally divided into the two groups: slow (n = 35) or
rapid (n = 35) progression according to their postural stability. Descriptive analysis was per-
formed using means ± SD values for continuous variables, and absolute and relative frequen-
cies for categorical variables. Statistical comparisons were performed using T-test for
independent samples for continuous variables and Chi-square test for categorical variables,
using R (version 3.0.3) and statistical significance set to p<0.05.
Blood sample collection
Venous blood from 70 PD patients was collected in PAXgene tubes (Qiagen) and stored at
-80°C prior to RNA extraction. Bias was minimized by collecting samples from both groups of
patients in parallel until all 70 samples were collected. All samples were then processed in par-
allel by a technician blinded to diagnosis.
Genetic Screening
Genomic DNA was extracted from peripheral blood using standard procedures. We screened
for mutations in the SNCA, PARK2 and LRRK2 genes. Analyses were carried out on each gene
via PCR using flanking intronic primers for all exons, followed by direct Sanger sequencing of
the PCR products in a ABI Prism 3100 (Applied Biosystems), using a BigDye v3.1 sequence kit
(Applied Biosystems).
RNA extraction and assessment of RNA quality
RNA isolation and purification was performed using PAXgene Blood RNA Kit (Qiagen),
according to the manufacturer’s instructions. RNA quality was monitored using a Bioanalyzer
(Agilent Tecnologies) and determined based on the RNA Integrity Number (RIN) package.
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Microarray analyses
Gene expression profiling was performed using RNA expression data generated by genome
array plates (Affymetrix Human Genome U219 platform, HG-U219) on total RNA extracted
from whole blood samples of the patients. The microarray data set has been submitted to
the GEO database (accession number GSE80599). The expression data was summarized and
normalized using Probe Logarithmic Intensity ERror estimation (PLIER) method through
Expression Console software (Affymetrix Inc) on all the platform Perfect Match (PM) probes,
composed of 49,386 probe sets. Quality control parameters of the microarrays included 3’ to 5’
ratio, labeling matrices, PMmean and polyA spike mean and probe cell intensity (S2 Fig). Prin-
ciple component analysis (PCA) identified two slow progression outlier samples, which were
removed from downstream analyses. In terms of gene pre-filtering, the top 15% non-variant
genes were removed prior to the analysis (leaving 17,011 of the 20,014 interrogated genes for
analysis). The first method for the evaluation of differential expression included an F test
(using the Bioconductor R package affylmGUI, R version 2.13.1)[18]. Additionally, we
removed covariate effects including hybridization batch, age and gender by a linear empirical
Bayes model [19] (S3 Fig). The expression data was analysed for differential expression using
Analysis of Variance (ANOVA), using Parket Genomics SuitTM, as well as a t-test including
bootstrapping for cross-validation using 1000 random iterations (p<0.001 considered as sig-
nificant). The detected genes were further validated by permutation-based test. Bootstrapping
and permutation t-tests were performed using MatlabR (R2011) software.
Pathway enrichment analysis
The functional enrichment analysis was conducted on genes detected as differentially
expressed, using DAVID resource EASE tool [20]. The enrichment was calculated for GO
terms and UP-SEQ features, SP-PIR keywords and KEGG pathways. In addition, GO network
analysis was conducted on the GO Biological Processes, through the Cytoscape [21] (version
3.1.0) plugin ClueGO [22], using Kappa Score.
Cell Culture
Lund Human Mesencephalic (LUHMES) cells were obtained, maintained and differentiated as
previously described[23]. Briefly, proliferating LUHMES cells were cultured in Advanced Dul-
becco’s modified Eagle’s medium/F12 (DMEM/F12, Gibco) supplemented with 1xN2 (Gibco),
2 mM L-glutamine (Gibco) and 40 ng/mL recombinant basic fibroblast growth factor (R&D
Systems). For differentiation, proliferation medium was replaced by DMEM/F12 containing
1xN2, 2 mM L-glutamine, 1 mM dibutyryl cAMP (Sigma Aldrich), 1 μg/mL tetracyclin
(Sigma-Aldrich) and 2 ng/mL recombinant human GDNF (R&D Systems). Two days (D2)
after adding differentiation medium, cells were seeded in plates (Nunclon) pre-coated with
50 μg/mL poly-L-ornithine and 1 μg/mL fibronectin (Sigma-Aldrich), and grown at 37°C in
humidified 5% CO2 atmosphere.
1-methyl-4-phenylpyridinium (MPP+) treatment and toxicity
measurement
On differentiation day 5 (D5) cells were treated with 2.5 μMMPP+ (Sigma-Aldrich) or control
dimethyl sulfoxide (DMSO, Roth). 72h later supernatants were collected and cell viability was
assessed by quantitatively measuring adenylate kinase content, using ToxiLight bioassay kit
(Lonza) according to the manufacture recommendations.
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RNA isolation and qPCR analysis
At day 8 (D8) of differentiation, total RNA extraction was performed using the RNeasy mini
kit (Qiagen). Total RNA was reverse-transcribed into cDNA using QuantiTect Reverse Tran-
scription Kit (Qiagen). For genes of interest, custom primers were designed using Primer 3
[24] (S1 Table). Human acidic ribosomal phosphoprotein P0 gene (RPLP0) was used as RNA
loading control, which exhibited consistent expression across all samples and was shown to
be the most suitable house keeping gene in peripheral blood mononuclear cells [25]. Equal
amplification efficiencies were confirmed for target and reference genes as appropriate and dis-
sociation curves were verified to ensure specific product generation. Samples were loaded in
triplicate and no-template controls were run on every reaction plate to exclude for genomic
DNA contamination. Amplification conditions were as follows: 5 minutes at 95°C, 40 cycles of
30 seconds at 95°C and 1.5 minutes at 60°C. Real-time PCRs (qPCRs) were performed using
Mx300P cycler (Agilent Tecnology) and MESA Blue qPCR MasterMix Plus for SYBR1 Assay
(Eurogentec). Ct values were obtained fromMxPro software and the comparative Ct method
was used for relative quantification of target genes. Gene expression levels were calculated as
relative expression compared to RPLP0, by subtracting Ct values from genes of interest to cor-
responding Ct values of the housekeeping gene (ΔCt). Subsequent ΔΔCt (ΔCt rapid progres-
sion-ΔCt slow progression) were calculated to assess fold change in rapid progression patients,
using the formula 2-ΔΔCt. Statistical analysis was performed using GraphPad Prism version
5.00. T-test for independent samples was used with significance at p0.05. Data is shown as
means ± SD of, at least, three independent experiments.
Immunocytochemistry analysis
At D8 of overall differentiation, cells were fixed with 4% paraformaldehyde for 10 minutes at
room temperature (RT). Following washing with PBS, cells were permeabilized in 0.5% Tri-
ton-X-100, for 15 minutes, and blocked with 1.5% normal goat serum in PBS (NGS), for 1h
at RT. Primary antibodies diluted 1:2000 in NGS were incubated overnight, at 4°C, and sec-
ondary antibodies were diluted 1:1000 and incubated for 2h at RT. Cell nuclei were stained
with Hoechst (Invitrogen), and imaging was performed using fluorescence microscopy Leica
DMI 6000B microscope (Leica, Wetzlar). Primary antibodies against tyrosine hydroxylase
(TH, polyclonal, rabbit, Millipore Corporation) and TUJ1 (monoclonal, mouse, Covance),
and secondary antibodies Alexa-Fluor 488 and 555 (Life Technologies) were used in this
study.
Results
Clinical characterization of rapid versus slow progression PD patients
First, we performed the clinical assessment of the 70 patients included in the study (35 slow
and 35 rapid progression patients). No significant differences concerning gender, age at motor
symptoms onset, age at examination, motor symptoms duration and family history between
the two groups existed (Table 1). As expected by the inclusion criteria and cohort stratification,
both disease staging (mHY scale) and postural stability (MDS-UPDRS 3.12) were significantly
different between the two groups (p<0.001). There was also a statistical significant difference
between the two groups on the total motor score (MDS-UPDRS III), on Gait (MDS-UPDRS
3.10) (p<0.001), on the Mini-Mental State Examination (MMSE) (p = 0.0030) and on the
Schwab and England activities of daily living scale (p<0.001). The fact that the two groups
have similar age of onset and duration of symptoms supports the pragmatic use of these criteria
to assume different rate of clinical progression in a cross-sectional study.
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Mutations in SNCA, PARK2 and LRRK2 do not discriminate between
rapid and slow PD progression
In order to determine whether known familial PD mutations were associated with the rate of
disease progression, we performed genetic screening on the SNCA, PARK2 and LRRK2 genes,
known to cause a substantial fraction of monogenic PD cases [27]. From the 70 patients tested,
we identified pathogenic mutations in the PARK2 gene in 2 cases: 1 of the patients carried the
previously described c.155delA, p.Asn52MetfsX29 mutation in heterozygous state[28], whereas
the other individual carried the c.1288G>A, p.Gly430Ser alteration in homozygous form (S2
Table). To our knowledge, this particular mutation was not previously reported, and should
therefore be investigated in future studies. We found the most common LRRK2mutation (c.
G6055A, p.Gly2019Ser) in 1 slow and 4 rapid progression PD patients, and some additional
polymorphisms in the PARK2 and LRRK2 genes. No mutations were detected in the SNCA
gene.
Identification of a molecular signature of PD progression in blood
Samples were processed and analysed in parallel to avoid bias induced by sample handling.
RNA quality was assessed using RIN in the two groups of patients, which displayed mean RIN
values of 7.14 (rapid progressors) and 7.02 (slow progressors). From the 70 RNA samples, 3
had RIN<6 and were not included in subsequent analysis (this corresponded to samples from
1 rapid and 2 slow progression patients). Thus, the expression analysis included 67 array sam-
ples. Clinical characterization of these 34 fast and 33 slow PD progression patients is described
in S3 Table. Demographic and clinical variables reaching statistically significant differences
between rapid vs slow progression groups remained the same, namely the total scores or sub-
scores of MDS-UPDRS III, MDS-UPDRS 3.10, MDS- UPDRS 3.12, mHY, SE and MMSE
scales. Also, age of onset and duration of symptoms between groups remained similar. All
Table 1. Clinical characterization of the cohort.
Rapid progression Slow progression p-value
n 35 35
Gender (% male) 45.7 51.4 0.811
Mean SD Mean SD
Age at motor symptoms onset 51.2 12.2 50.6 11.9 0.8304
Age at examination 70.0 8.4 66.3 8.7 0.8024
Motor symptoms duration 18.8 8.2 15.7 6.7 0.09584
MDS-UPDRS III 50.7 16.1 32.2 12.9 <0.001
Postural stability MDS-UPDRS 3.12 2.1 1.1 0.0 0.0 <0.001
Gait MDS-UPDRS 3.10 1.9 1.1 0.9 0.8 <0.001
Modiﬁed Hoehn and Yahr stage 3.0 0.8 2.0 0.2 <0.001
SE Scale 59.3 20.6 81.8 13.8 <0.001
MMSE 24.6 4.6 27.5 2.9 0.00304
Levodopa equivalent dose (mg)* 1050.2 553.3 840.7 444.0 0.08976
Family History (% yes) 34.3% 37.1%
Clinical assessment of the 70 patients included in the study. MDS-UPDRS: Movement Disorder Society- Uniﬁed Parkinson’s Disease Rating Scale; HY:
Modiﬁed Hoehn and Yahr stage; SE: Schwab and England activities of daily living scale; MMSE- Mini mental stage examination
* Levodopa equivalent dose[26].
doi:10.1371/journal.pone.0157852.t001
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microarray analyses were conducted following extensive quality control including sample and
probe filtering. Two outlier samples of two slow progression patients were detected based on
PCA analysis and were removed from further analysis. The remaining samples served for all
downstream data analysis. 1,251 probe sets were detected using ANOVA at significance level
of p0.05 (138 at p<0.01), including the SNCA gene encoding for alpha-synuclein, a main pro-
tein component of Lewy bodies (S4 Table). T-test using bootstrapping was applied for cross-
validation, identifying 1,080 differentially expressed genes (p<0.005) (S5 Table). 219 of those
genes were also detected by a permutation based t-test, which identified overall 221 genes as
altered (p<0.05, 25 at p<0.01), reflecting the robustness of the findings (S6 Table). Hierarchi-
cal clustering classification based on their expression signals correctly classified 28/33 of the
slow progression PD patients and 23/34 of the rapid progression patients (Fig 1).
Interestingly, functional enrichment analysis revealed high enrichment of biological terms
related to nucleic acid metabolism/repair, intracellular transport, transcription regulation, and
immune function (S1 Appendix). Further analysis by the Cytoscape plugin ClueGO, using dif-
ferential expressed genes on bootstrapping t-test, also yielded high enrichment in nucleic acids
metabolic processing gene ontology (GO) terms (Fig 2).
Other studies showed that these molecular processes are affected in PD. Strikingly, microar-
ray analysis of blood from PD patients and healthy controls identified 20 deregulated genes
[11], 6 of which were also deregulated in our cohort (BCL11B, PRPF4B, NAP1L1, SERPINB9,
Fig 1. Hierarchical clustering of genes detected as differentially expressed in rapid versus slow progression PD patients.Classification
based on expression signals of the bootstrapping t-test-detected genes resulted in only five mis-classified slow and 11 mis-classified rapid
progression patients. The color bar denotes z-score adjusted expression values, green used for lower expression and purple for higher expression
levels. Eucledian distance and average linkage methods were used.
doi:10.1371/journal.pone.0157852.g001
Molecular Markers of PD Progression
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Fig 2. Functional network of the differentially expressed genes altered in PD patients having slow versus rapid disease progression.
GO network analysis on the GO biological process terms that were found as highly enriched in blood cells from slow versus rapid progression
patients. The node circle size represents the number of altered genes in the category, and the categories colours correspond to the functional
group.
doi:10.1371/journal.pone.0157852.g002
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LRPPRC, TCEA1). From those, PRPF4B, a pre-mRNA processing factor, NAP1L1, a nucleo-
some assembly protein, and TCEA1, a transcription elongation factor, are involved in nucleic
acid metabolism. Two of the genes identified were also altered in PD patients upon Deep Brain
Stimulation (DBS) [9]. One of the genes, LRRC8C, is a component of the volume-regulated
anion channel and was also identified in an exon array study in PD leukocytes [29] and in
mouse models of the disease [30]. The other, HNRPDL, belongs to the family of heterogeneous
nuclear ribonuclearproteins and is involved in RNA processing. From 10 genes found deregu-
lated in the prefrontal cortex of PD patients, 2 were also differentially deregulated between
slow and rapid progression patients [31]. These were RNF138, an E3 ubiquitin protein ligase,
and SEC24B, involved in vesicle trafficking. Another important vesicular trafficking gene,
VAMP1, was also deregulated in our dataset and in the susbtantia nigra of PD patients [32]. A
meta-analysis study on gene sets that combined data from several expression studies in periph-
eral and brain cells, revealed a major involvement of mitochondrial genes and bioenergetics
changes in PD pathology [33]. Although PPARGC1A, suggested as a potential therapeutic tar-
get in PD, was not detected as differentially expressed in this study, our analysis revealed
enrichment in genes involved in mitochondrial processes. Remarkably, we identified 42 genes
(S7 Table) that were also deregulated in brain tissue fromMPTP-treated mice, an established
model of PD [30]. The common genes were mostly involved in nucleic acid processing,
immune response, mitochondria, and metal ion transport. Additionally, a microarray study
using SH-SY5Y cells treated with MPP+ reported strong deregulation genes involved in tran-
scription [34]. Therefore, genes controlling nucleic acid metabolism, immune response and
mitochondrial processes may be detrimental in dopaminergic cell death and disease
progression.
Validation of transcriptionally-deregulated genes by qPCR
Based on their functional relevance and potential involvement in PD progression, we selected
10 genes that showed differential expression between rapid and slow progression patients, and
confirmed their pattern of expression using qPCR. Detailed GO analysis for the selected genes
is displayed in S8 Table. The validation was conducted on samples from a subset of patients (8
rapid and 8 slow progression patients). The expression changes obtained in qPCR assays were
consistent with those observed in the microarray experiments. 8 out of these 10 genes showed
significant expression differences, whereas changes in 2 genes did not reach statistical signifi-
cance (FHL1, 1.48 fold-change, p = 0.16; APC 1.02 fold-change, p = 0.34). Up-regulated genes
included RAD18 (2.19 fold-change, p = 0.002), ABCA1 (3.09-fold change, p = 0.0009) and
AGAP1 (2.92 fold-change, p = 0.003), while FOXP1 (0.35 fold-change, p = 0.007), PPAT (0.31
fold-change, p = 0.0003), NUB1 (0.41 fold-change, p = 0.002), AKT2 (0.48 fold-change,
p = 0.019 and ABI2 (0.69 fold-change, p = 0.02) were down-regulated (Fig 3).
We further evaluated the expression of 4 of these genes (RAD18, ABCA1, AGAP1 and
FOXP1) in an additional set of samples– 5 rapid and 5 slow progressors. Importantly, we con-
firmed significant differences in the expression of these genes between the two groups of sam-
ples (S4 Fig).
The molecular signature of blood cells from PD patients is reproduced in
an acute cell model of PD
Next, we investigated the expression of the 7 genes exhibiting the largest expression differences
in a cell model of PD based on the treatment of differentiated LUHMES cells with a toxin,
MPP+. These dopaminergic-like cells exhibited high sensitivity to low concentrations of MPP+
(Fig 4A, 4B and 4C). qPCR analysis showed that 6 out of these 7 genes were differentially
Molecular Markers of PD Progression
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Fig 3. Selected genes investigated by qPCR in PD patients-derived samples. -ΔCts plotted for 10 genes chosen for qPCR validation in
cDNA obtained from 16 patients with either slow or rapid progression of the disease. Data is expressed as means ± SD of triplicates. T-test
was used for statistical analysis with significance level of p<0.05. *p<0.05; **p<0.01; ***p<0.0005.
doi:10.1371/journal.pone.0157852.g003
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Fig 4. Selected genes investigated in a LUHMES/MPP+ cell model of PD. (A) LUHMES cells treated with solvent (DMSO) or 2.5μMMPP+
stained for Tyrosine Hydroxylase (TH), TUJ1 and nucleus or (B) observed in bright field, showed robust loss of neurite integrity upon MPP+
treatment. (C) Cell viability analysis assessed by ToxiLigh assay revealed a significant increase of adenylate kinase content in the supernatants
of MPP+ treated cells. (D) -Δcts plotted for seven genes chosen for validation using D8 differentiated LUHMES cells exposed to 2.5μmMPP+.
(E) Correlation between fold-change expression values obtained in LUHMES/MPP+ model and PD patients. Data is expressed as means ± SD
of triplicate samples. T-test was used for statistical analysis with significance level of p<0.05. *p<0.05; **p<0.01. Scale bar 100 μm.
doi:10.1371/journal.pone.0157852.g004
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expressed (p<0.05) in cells treated with 2.5 μMMPP+. One of the genes did not reach signifi-
cance (AKT2, 0.9 fold-change, p = 0.48). Expression changes of 5 genes were similar to those
observed for rapid progression PD patients: ABCA1 (2.35-fold change), AGAP1 (1.69 fold-
change), FOXP1 (0.55 fold-change), PPAT (0.38-fold change) and NUB1 (0.77-fold change).
Interestingly, RAD18 was down-regulated in MPP+ treated cells (0.24-fold change) and was
up-regulated in rapid versus progression patients (Fig 4D). Overall, changes in LUHMES cells
treated with MPP+ were highly consistent with the expression changes observed in PD patients
with varying disease progression (Fig 4E).
Discussion
Here, we report on a novel cross-sectional, exploratory study aiming at determining whether
gene expression analysis of RNA samples from easily accessible body fluids (e.g. blood) may
allow the identification of molecular signatures that discriminate disease progression in neuro-
degenerative conditions, such as in PD. Moreover, our translational approach establishes an
important bridge between the clinics and the bench, demonstrating that deregulated pathways
in patients with varying disease progression are similarly altered in a cell model of PD. In our
view, future studies should focus on the detailed investigation of each of the identified genes in
order to decipher the individual role of these genes in PD and, in particular, in dopaminergic
cell death, and the validity of specific molecular signatures as peripheral predictors of PD
progression.
With respect to the clinical criteria, we overcame the limitations of a cross-sectional study
design to compare two groups of patients with assumed different rate of disease progression.
The disease duration of 10 years as lower limit for recruitment enabled us to generate two
groups with clear different disability but not significant difference on disease duration and age
of onset. This is consistent with the consideration that the two groups have different rates of
progression concerning clinically relevant outcomes, such as postural instability. Also, support-
ing our strategy of separating rapid versus slow progression based in postural instability is the
fact that, although no significant differences in age at onset (rapid 51.6±12.1yr versus slow 51.5
±11.6yr; p = 0.956) and in disease duration (rapid 18.3±7.8yr versus slow 15.5±6.8yr; p = 0.956)
were observed between the two groups, the rapid progression group showed significant statisti-
cal differences in other clinical outcomes known to be associated with more advanced disease
stages, such as higher score in MDS-UPDRS III, lower score in the SE scale, and lower score in
MMSE. This reflects a more impaired motor status, stronger dependency in activities of daily
living, and a worse cognitive profile, respectively. Although not statistically significant, mean
levodopa equivalent dose was slightly higher in the rapid progression group, in line with the
perception of the physicians for the need to treat higher motor impairment. Conversely, it does
not allow concluding that the slower group has a better motor status due to medication levels.
To ascertain the molecular determinants of disease progression in PD, we investigated gene
expression profiles of the two groups of PD patients. We identified several genes differentially
expressed between rapid and slow progression patients. Functional enrichment analysis
revealed multiple signalling pathways associated with PD progression. To further confirm if
these were relevant pathways, we asked whether genes whose expression was found altered in
our study had been previously identified in other studies, with samples from either PD patients
or from models of the disease. Among the genes found to be altered, we found that SNCA was
downregulated in rapid progressors. This data was intriguing since duplications and triplica-
tions of SNCA are known causes of familial PD. However, it was previously shown that periph-
eral changes may be considerably paradoxical. Along the same lines, a recent study revealed
that, in blood, lower SNCA transcript levels are associated with early-stage PD and correlate
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with cognitive decline [35]. We also identified several differentially expressed genes that were
previously found to be altered in blood cells from early PD patients, in leukocytes from
advanced PD patients post DBS surgery, and in genetic and toxin-based mouse models of PD
[9, 29, 30]. Particularly, common genes were mostly involved in nucleic acid metabolism,
immune response and mitochondrial processes. The expression of selected genes, involved in
those pathways, was confirmed by qPCR.
Although the current animal models of PD fail to fully recapitulate all aspects of the disease,
models based on MPP+ intoxication are still valuable tools to assess the effects associated with
selective impairment of dopaminergic neurons. MPP+ has been shown to cause acute parkin-
sonism and dopaminergic neurons death in humans [36], and to rapidly induce motor decline,
resembling PD symptomology, in primates [37]. As dopaminergic cell loss and motor disease
progression may be closely related, we evaluated the expression of deregulated genes in a dopa-
minergic cell-based model. LUHMES cells treated with MPP+ were used as a tractable in vitro
PD model, affording a simple system to dissect the contribution of the selected pathways on
dopaminergic cell death. In particular, our approach confirmed that genes controlling nucleic
acid metabolism and DNA repair, mitochondria, immune response and intracellular-transport
may be detrimental in dopaminergic cell viability.
Surprisingly, we found that while RAD18 was up-regulated in rapidly-progressing PD
patients, it was down-regulated in LUHMES cells treated with MPP+. RAD18 is a highly con-
served E3 ubiquitin-ligase that integrates a multi-protein complex responsible for post replica-
tion repair of multiple DNA lesions [38, 39]. Thus, the up-regulation of RAD18 in blood cells
of rapid progressing patients might reflect a response to cellular stress. Our findings suggest
that the types of stress tested in LUHMES cells may induce different responses from those
sensed in peripheral cells. Consistently, in a previous study using primary cortical neurons
exposed to Aβ 1–40, a natural antisense transcript against RAD18 (NAT-RAD18) was found to
be up-regulated, whereas RAD18 was down-regulated[40]. Notably, besides RAD18, we found
several other genes involved in DNA repair, such as RAD51, TOP1, TP53, POL2A and multiple
members of the POL family. Our study suggests that alterations in nucleic acid metabolism,
particularly in DNA repair, may constitute a key event in PD. Thus, although there is growing
evidence implicating DNA damage in neurodegenerative processes [41–44], we uncovered, for
the first time, a role for DNA repair systems in PD progression.
Another relevant finding was that the forkhead box protein P1 (FOXP1), a transcription fac-
tor implicated in diverse roles in the immune system in peripheral and brain tissues[45, 46],
was significantly down-regulated both in rapid progression patients as well as in LUHMES
cells treated with MPP+. Decreased FOXP1 expression may result in increased levels of pro-
inflammatory mediators, including damaging cytokines and chemokines [47].
Several ATP-binding cassette (ABC) transporters, primarily known for their role in intracel-
lular transport but also involved in DNA repair, were found altered in our dataset. ABCA1, a
cholesterol and phospholipid transporter, was significantly up-regulated both in patients with
rapid progression and in MPP+-treated LUHMES cells. Since up-regulation of ABCA1may
lead to alter high-density lipoprotein biogenesis[48, 49] in blood, future studies should assess
cholesterol levels in PD patients to determine whether these are related to differential disease
progression.
Glutamine phosphoribosylpyrophosphate amidotransferase (PPAT) is a key enzyme of the
purine biosynthesis and requires the incorporation of an iron-sulphur (Fe-S) cluster for its
maturation[50]. Importantly, our finding that PPAT is consistently down-regulated both in the
blood of rapid progression patients and in LUHMES cells treated with MPP+, underscores a
pivotal role for DNA synthesis/repair systems, mitochondria and iron homeostasis in PD
progression.
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Given that Lewy Bodies (LBs) are a major hallmark of PD, it has long been hypothesized
that protein quality control pathways might constitute attractive reporters for disease progres-
sion and targets for pharmacological intervention. Here, we found that NUB1 was down-regu-
lated in rapid progression patients and in LUHMES treated with MPP+. NUB1, a negative
regulator of ubiquitin-like proteins, was shown to enhance proteasomal degradation of the
aSyn-interacting protein synphilin-1[51], to enhance tau phosphorylation and aggregation
[52], and to co-localize with presynaptic PK-resistant aSyn in the brains of patients with
dementia with LB [53]. Thus, lower NUB1 expression might impair protein degradation and
lead to LB formation.
Also, a member of the ADP-ribosylation factor GTPase-activating protein family, AGAP1,
was found up-regulated both in rapid progression patients and in LUHMES cells treated with
MPP+, suggesting that cytoskeleton dynamics, and membrane trafficking may be important
processes in PD. More importantly, AGAP1 was recently shown to mediate the binding of the
adapter protein-3 to the muscarin receptor 5 (M5), which are involved in dopamine neuro-
transmission in the striatum[54].
The strong correlation between the gene expression changes in PD patients and in cell mod-
els suggests that peripheral tissues may reflect important disease-related mechanisms taking
place in the brain, despite obvious and inherent limitations of dissociated cell models.
To the best of our knowledge, this is the first study aimed at identifying molecular pathways
distinguishing PD progression in peripheral blood. In total, we report novel, relevant genes
that can be scrutinized in prospective studies, and that may prove valuable for distinguishing
rapid versus slow PD progression phenotypes. Our findings suggest a possible mechanistic link
between altered DNA synthesis/repair systems, intracellular transport, immune response, tran-
scription regulation and the prediction of PD prognosis. Despite certain limitations, such as
the need for fully validating the identified gene expression differences in well-characterized,
independent cohorts, and that the classification of slow versus rapid progression may be a sim-
plified view of the known heterogeneous rates of disease progression, we were able to identify a
molecular signature that distinguishes both groups of patients. In future studies, one might per-
haps attempt to use other disease progression classifiers. In our study, we used a classification
based on previous reports showing that the absence of motor instability after 10 or more years
of symptom onset is related to a slower progression phenotype, but it should be clarified that,
to the best of our knowledge, there are no standardized clinical scales to unambiguously distin-
guish rapid from slow progressors thus far. Finally, our findings should be confirmed in longi-
tudinal studies, due to obvious limitations of a cross-sectional study. In such longitudinal
studies, it is possible that peripheral predictors of disease progression might be unequivocally
identified, which would be an invaluable aid for both clinicians and patients suffering from PD.
Nevertheless, and despite the limitations, our exploratory study may also be relevant for
other neurodegenerative disease with varying progression rates (such as Amyotrophic lateral
sclerosis), and may open novel avenues for investigating and modelling PD progression in
model systems, and the identification of targets for therapeutic intervention.
Supporting Information
S1 Appendix. Functional enrichment analysis conducted through the DAVID resource
EASE [56] tool, on differentially expressed genes changed in PD progression.
(XLSX)
S1 Fig. Schematic representation of the overall experimental design. Gene expression analy-
sis was conducted on RNA samples derived from PD patients and a cellular PD model. (A) The
experimental design employed to investigate a gene signature of PD progression in patients is
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depicted on the left side of the schematic. PD patients (n = 70) were clinically characterized by
either a slow or rapid disease progression. Gene expression analysis was performed on 67 sam-
ples using Affymetrix DNA 3’U219 microarray plates. Multiple statistical approaches allowed
the identification of differentially expressed genes. 10 genes were used for further validation by
qPCR. (B) From those we selected the 7 most promising genes to further investigate their
expression in a cellular model of PD based on MPP+ treatment of differentiated LUHMES
cells.
(TIF)
S2 Fig. Quality control measurements for the microarray data. Plots showing the concentra-
tion of the microarray control spike-in probes and the probe cell intensities for all samples (x-
axis: sample 1 to 67). (A) The log of probe cell intensity after normalization and summary (B)
A line graph of the PM probes mean with polyA spike RLE mean. (C) A line graph of Affyme-
trix labeling matrices and (D) a line graph of Affymetrix 3’ to 5’ ratio values.
(TIF)
S3 Fig. Empirical Bayes batch effect parameter estimates using parametric empirical priors.
The effects of age and gender covariates were removed (using ComBat software) prior to the
differential expression analysis. The plots show the sample quantiles and density (A) prior to
and (B) following the effects removal. The first step is gene-wise standardization of the normal-
ized data (as the magnitude of expression values could differ across genes due to mRNA
expression level and probe Sensitivity). This is followed by Empirical Bayes batch effect param-
eter estimates using parametric empirical priors. Dotted lines on the quantile–quantile plots
correspond to the EB-based Normal or Inverse Gamma distributions.
(TIF)
S4 Fig. Validation of 4 of the selected genes in additional samples derived from PD
patients. –ΔCt values plotted for 4 genes (RAD18, ABCA1, FOXP1 and AGAP1) chosen for
qPCR validation in 10 additional patients with either slow or rapid progression of the disease.
Data is expressed as mean ± SD of triplicates. T-test was used for statistical analysis with signif-
icance level of p<0.05. p<0.05; p<0.01.
(TIF)
S1 Table. Sequences of primers used in the study. Primers used in this study to measure gene
expression level by qPCR.
(PDF)
S2 Table. Genetic screening of the PD patients included in the study.Mutations in the
SNCA, PARK2 and LRRK2 genes were screened in genomic DNA extracted from peripheral
blood. Neg.: no mutations found.
(PDF)
S3 Table. Clinical assessment of the 67 patients included in clinical and gene expression
analysis.MDS-UPDRS: Movement Disorder Society- Unified Parkinson’s Disease Rating
Scale; HY: Modified Hoehn and Yahr stage; SE: Schwab and England activities of daily living
scale; MMSE- Mini mental stage examination; Levodopa equivalent dose.
(PDF)
S4 Table. Genes detected as differentially expressed in PD patients with rapid compared to
slow progression disease, through ANOVA.
(PDF)
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S5 Table. Genes differentially expressed detected by bootstrapping (n = 1000 iterations) t-
test having p<0.005. The analysis was conducted on averaged gene expression values based
on the summarized and normalized expression data following covariate correction.
(PDF)
S6 Table. Genes detected as differentially expressed between slow and rapid progression
PD patients identified by t-test with permutations.
(PDF)
S7 Table. Genes changed in PD progression and in MPTP/SNCA data sets microarray meta
analysis[30].
(PDF)
S8 Table. GO analysis of selected genes for qPCR validation. Analysis was conducted
through DAVID[55].
(PDF)
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